Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06186063
Other study ID # H-22050946
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 12, 2024
Est. completion date August 1, 2024

Study information

Verified date February 2024
Source University Hospital, Gentofte, Copenhagen
Contact Mathilde K. Preskou, MD
Phone +45 2349 6823
Email emma.mathilde.kirsmeier.preskou.01@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical study aims to investigate the effect of the intravenously administrated amylin analogue (pramlintide) on the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) (a marker of bone resorption) and N-terminal propeptide of type I procollagen (P1NP) (a marker of bone formation) in individuals with type 1 diabetes and matched healthy controls during fasting euglycemic conditions.


Description:

Using a randomised double blinded placebo-controlled crossover design the investigators will evaluate the effects of the intravenously administrated amylin analogue (pramlintide) on circulating levels of CTX-1 and P1NP in ten individuals with type 1 diabetes and ten healthy controls matched for age, gender and body mass index (BMI) during fasting and euglycemic conditions. Each participant will receive double-blinded infusions of pramlintide (3 pmol/kg/min) and saline on two separate study days performed in randomised order. The primary endpoints are the relative changes in the plasma levels of P1NP and CTX-1. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma CTX-1 and P1NP as well as %-changes from baseline including nadir. The secondary endpoints encompass changes in plasma concentrations of calcium, parathyroid hormone (PTH), alkaline phosphatase, osteocalcin, glucagon, insulin, C-peptide, glucose, glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 and glucagon-like peptide 2.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 1, 2024
Est. primary completion date August 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion criteria type 1 diabetes: - Caucasian ethnicity - Age between 18 and 60 years - BMI between 18.5 and 27 kg/m2 - Type 1 diabetes (diagnosed according to the criteria of the World Health Organization) with HbA1c <69 mmol/mol (<8.5%) and - Type 1 diabetes duration of 2-20 years - C-peptide negative (stimulated C-peptide =30 pmol/l) - Treatment with a stable basal-bolus or insulin pump regimen for =3 months - Normal vitamin D (>50 nmol/l) - Informed consent Exclusion criteria type 1 diabetes: - Anaemia (haemoglobin below normal range) - Liver disease (ALAT and/or ASAT >2 times normal values) or history of hepatobiliary disorder - Nephropathy (eGFR <60 ml/min/1,73m2 and/or microalbuminuria) - Microvascular complications except non-proliferative retinopathy - Treatment with anti-osteoporosis medication or glucocorticoids - Fractures within the last 6 months - For women: currently perimenopausal or postmenopausal - Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer) - Pregnancy or breastfeeding - Any physical or psychological condition that the investigator feels would interfere with trial participation - Treatment with any glucose-lowering drugs beside insulin, treatment with medication against osteoporosis or treatment with any form of glucocorticoids Inclusion criteria healthy controls: - Caucasian ethnicity - Age between 18 and 60 years - BMI between 18.5 and 27 kg/m2 - Fasting plasma glucose =7.0 mmol/l and glycated haemoglobin (HbA1c) <48 mmol/mol - Normal blood haemoglobin (8.3-10.5 mmol/l (males) and 7.3 - 9.5 mmol/l (females)) - Normal plasma vitamin D (>50 nmol/l) - Informed consent Exclusion criteria healthy controls: - Any form of diabetes (according to World Health Organization criteria) - Anaemia (haemoglobin below normal range) - Nephropathy (eGFR <60 ml/min/1,73m2 and/or microalbuminuria) - Known liver disease and/or alanine transaminase (ALAT) or aspartate transaminase (ASAT) >2 × upper normal limit - Any fractures within the last 6 months - For women: currently perimenopausal or postmenopausal - Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer) - Pregnancy or breastfeeding - Any condition considered incompatible with participation by the investigators

Study Design


Intervention

Other:
Pramlintide
At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
Placebo (saline) infusion
At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.

Locations

Country Name City State
Denmark Center for Clinical Metabolic Research, Gentofte Hospital Hellerup Capital Region

Sponsors (1)

Lead Sponsor Collaborator
Filip Krag Knop

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative changes in the plasma levels of C-terminal telopeptide of type I collagen (CTX-1) The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma CTX-1 as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Primary Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP) The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma P1NP as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of glucagon. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of insulin. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of C-peptide. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of glucose. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of glucose-dependent insulinotropic polypeptide (GIP). The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of glucagon-like peptide 1 (GLP-1). The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of glucagon-like peptide 2 (GLP-2). The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of calcium. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of parathyroid hormone (PTH) The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of alkaline phosphatase The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
Secondary Changes in plasma concentrations of osteocalcin The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir. From -15 minutes to 180 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4